Abstract
Objectives Observational analyses suggest that high Bone Mineral Density (BMD) is a risk factor for osteoarthritis (OA); it’s unclear whether this represents a causal effect or shared aetiology and whether these relationships are body mass index (BMI)-independent. We performed bidirectional Mendelian randomization (MR) to uncover the causal pathways between BMD, BMI and OA.
Methods One-sample (1S)MR estimates were generated by two-stage least-squares regression. Unweighted allele scores instrumented each exposure. Two-sample (2S)MR estimates were generated using inverse-variance weighted fixed-effects meta-analysis. Multivariable MR (MVMR), including BMD and BMI instruments in the same model, determined the BMI-independent causal pathway from BMD to OA. Latent causal variable (LCV) analysis, using weight-adjusted FN-BMD and hip/knee OA summary statistics, determined if genetic correlation explained the causal effect of BMD on OA.
Results 1SMR provided strong evidence for a causal effect of eBMD on hip and knee OA (ORhip =1.28[1.05,1.57],p=0.02, ORknee =1.40[1.20,1.63],p=3×10−5, OR per SD increase). 2SMR effect sizes were consistent in direction. Results suggested that the causal pathways between eBMD and OA were bidirectional (βhip=1.10[0.36,1.84],p=0.003, β knee =4.16[2.74,5.57],p=8×10−9, β=SD increase per doubling in risk). MVMR identified a BMI-independent causal pathway between eBMD and hip/knee OA. LCV suggested that genetic correlation (i.e. shared genetic aetiology) did not fully explain causal effects of BMD on hip/knee OA.
Conclusions These results provide evidence for a BMI-independent causal effect of eBMD on OA. Despite evidence of bidirectional effects, the effect of BMD on OA did not appear to be fully explained by shared genetic aetiology, suggesting a direct action of bone on joint deterioration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Wellcome Trust (grant ref 20378/Z/16/Z). CLG was funded by Versus Arthritis (grant ref 20000). JZ receives salary and start-up funding from the University of Bristol (Vice-Chancellor's fellowship). JZ is also supported by the Academy of Medical Sciences (AMS) Springboard Award, the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation and Diabetes UK (SBF006\1117). AH, ES, RG, LP, JZ, GDS, CLG and JHT work in, or are affiliated with, a University of Bristol and MRC funded unit (MC_UU_00011/1, MC_UU_00011/4).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethical approval from the Research Ethics Committee (REC reference:11/NW/0382). UK Biobank analyses have been conducted under approved research project 17295.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵5 A list of members and affiliations appears in the Supplementary Information
Data Availability
UK Biobank data are available through a procedure described at https://www.ukbiobank.ac.uk/principles-of-access/. BMD GWAS summary statistics are available to download from the GEFOS website at http://www.gefos.org/?q=content/gefos-data-release. GIANT BMI GWAS summary statistics are available to download at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files#GIANT_Consortium_2012-2015_GWAS_Summary_Statistics. Hip and knee OA GWAS summary statistics from UK Biobank and arcOGEN are publicly available at https://www.ebi.ac.uk/gwas/.
